| Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress | 05/16 08:30 | businesswire.com |
| Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference | 04/30 08:30 | businesswire.com |
| Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors | 04/29 08:30 | businesswire.com |
| Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? | 04/12 09:26 | zacks.com |
| 3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 | 04/11 12:24 | investorplace.com |
| Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) | 04/08 11:48 | businesswire.com |
| 7 Biotech Stocks Ready to Ride the Sector's Resurgence | 03/18 20:01 | investorplace.com |
| Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript | 03/13 10:01 | seekingalpha.com |
| Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights | 03/13 07:05 | businesswire.com |
| Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) | 03/13 07:00 | businesswire.com |